Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

68.94 +0.62 (+0.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗
 
Via Benzinga
Where Arcellx Stands With Analysts ↗
 
Via Benzinga
News headline image
Why Is Arcellx (ACLX) Stock Up 25% Today? ↗
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business. 
Via InvestorPlace
News headline image
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
News headline image
20 Favorite Biotech & Medical Stocks For 2023 ↗
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
News headline image
Dow Tumbles 100 Points; Silver Rises Over 2% ↗
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
News headline image
US Stocks Turn Higher; Nasdaq Rises 40 Points ↗
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences ↗
The company inked a deal worth $325 million and up to $3.9 billion in milestones. 
Via Investor's Business Daily
News headline image
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
News headline image
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected ↗
U.S. stocks traded slightly lower this morning following the release of PPI data 
Via Benzinga
News headline image
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate ↗
 
Via Benzinga
News headline image
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗
Upgrades 
Via Benzinga
News headline image
More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying ↗
Although the US stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide ↗
U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
News headline image
37 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares jumped 153% to $2.94 after the company announced it received notification of euro 782.1 million of funding from the Greek State for the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
82 Biggest Movers From Yesterday ↗
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
41 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy. 
Via Benzinga
News headline image
91 Biggest Movers From Friday ↗
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
News headline image
69 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.